UK's Spire Healthcare H1 hit by lower NHS activity, higher costs

By Reuters News


Overview

  • UK healthcare provider's H1 revenue dipped 0.8% as NHS activity declined

  • Adjusted EBITDA for H1 fell 16.6%, reflecting cost inflation and lower NHS revenue

  • Adjusted free cash flow rose 35.3% on improved capital efficiency and lower capex


Outlook

  • Spire Healthcare continues to target FY26 adjusted EBITDA broadly in line with FY25

  • Company says demand for independent healthcare remains strong, with growth in private payor revenues

  • Spire Healthcare says visibility over NHS activity remains strong, with >95% of 2026/27 plan revenue agreed


Result Drivers

  • NHS REVENUE DECLINE - Lower NHS activity, especially a 24.9% drop in Q1, weighed on overall revenue and profitability

  • PRIVATE PAYOR GROWTH - Self-Pay and PMI revenues rose, supported by commercial initiatives and continued demand for private healthcare

  • COST INFLATION - Profitability was pressured by inflation across a largely fixed cost base, limiting the ability to offset NHS revenue shortfall


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

H1 Revenue

GBP 792.70 mln

H1 Adjusted EBITDA

GBP 112.40 mln

H1 Adjusted EBIT

GBP 50.60 mln

H1 Adjusted Free Cash Flow

GBP 20.70 mln

H1 Pretax Loss

GBP 14.80 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the healthcare facilities & services peer group is "buy"

  • Wall Street's median 12-month price target for Spire Healthcare Group PLC is GBp262.50, about 6.9% above its September 29 closing price of GBp245.50

  • The stock recently traded at 15 times the next 12-month earnings vs. a P/E of 22 three months ago


Reuters Recommended Reads

  • Sept 29 - Close Brothers FY 2026 adjusted profit falls; not paying annual dividend

  • Sept 29 - Close Brothers profit beats expectations as restructuring progresses

  • Sept 28 - Can the UK forge a new era of reindustralisation?


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.